The microbiota–gut–brain axis and its modulation in the therapy of depression: Comparison of efficacy of conventional drugs and traditional Chinese medicine approaches
Authors:
- 28 July 2022
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 183, 106372
Abstract
No abstract availableKeywords
Funding Information
- Medical Science and Technology Project of Zhejiang Province (2020KY332)
This publication has 126 references indexed in Scilit:
- Gut–brain axis: how the microbiome influences anxiety and depressionTrends in Neurosciences, 2013
- The Impact of the Gut Microbiota on Human Health: An Integrative ViewCell, 2012
- Correlations between brain-derived neurotrophic factor and clinical symptoms in medicated patients with major depressionJournal of Affective Disorders, 2011
- The anxiolytic effect of Bifidobacterium longum NCC3001 involves vagal pathways for gut-brain communicationNeurogastroenterology & Motility, 2011
- Antidepressants and Body WeightThe Journal of Clinical Psychiatry, 2010
- Principles and clinical implications of the brain–gut–enteric microbiota axisNature Reviews Gastroenterology & Hepatology, 2009
- Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patientsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2009
- The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the ratJournal of Psychiatric Research, 2008
- New approaches to antidepressant drug discovery: beyond monoaminesNature Reviews Neuroscience, 2006
- Low Brain-Derived Neurotrophic Factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivityBiological Psychiatry, 2005